-
公开(公告)号：US09227949B2
公开(公告)日：2016-01-05
申请号：US14567506
申请日：2014-12-11
Applicant: AJINOMOTO CO., INC.
Inventor： Takahiro Koshiba , Munetaka Tokumasu , Taisuke Ichimaru , Koji Ohsumi , Tadakiyo Nakagawa , Tatsuhiro Yamada , Kayo Matsumoto , Tamotsu Suzuki
IPC: A61K31/38 , C07D319/12 , C07D333/38 , C07D409/06 , C07D409/12 , C07D333/40
CPC classification number: A61K31/381 , A61K31/19 , A61K31/396 , A61K31/397 , A61K31/4025 , A61K31/41 , A61K31/4436 , A61K31/4535 , A61K31/4725 , A61K38/05 , C07D319/12 , C07D333/38 , C07D333/40 , C07D409/06 , C07D409/12
Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
Abstract translation: 由下式（I）表示的化合物; 其中每个符号如说明书中所定义，可用作具有丝氨酸蛋白酶抑制作用的高血糖抑制剂和用作糖尿病的预防或治疗药物。
-
公开(公告)号：US20140080790A1
公开(公告)日：2014-03-20
申请号：US14089040
申请日：2013-11-25
Applicant: AJINOMOTO CO., INC.
Inventor： Atsushi KONISHI , Munetaka Tokumasu , Tamotsu Suzuki , Takahiro Koshiba , Koji Ohsumi , Osamu Ikehara , Yuko Kodama
IPC: C07D307/68 , C07D405/06 , C07F9/655 , C07C53/18
CPC classification number: A61K31/4535 , A61K31/341 , A61K31/381 , A61K31/4025 , A61K31/426 , A61K31/4525 , C07C53/18 , C07D277/20 , C07D277/56 , C07D307/68 , C07D333/38 , C07D405/06 , C07F9/3808 , C07F9/65515
Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书中所定义，及其药学上可接受的盐可用作具有丝氨酸蛋白酶抑制作用的高血糖抑制剂和用作糖尿病的预防或治疗药物。
-
公开(公告)号：US08877805B2
公开(公告)日：2014-11-04
申请号：US14089040
申请日：2013-11-25
Applicant: Ajinomoto Co., Inc.
Inventor： Atsushi Konishi , Munetaka Tokumasu , Tamotsu Suzuki , Takahiro Koshiba , Koji Ohsumi , Osamu Ikehara , Yuko Kodama
IPC: A61K31/341 , C07D277/20 , C07D333/38 , C07D277/56 , C07D307/68 , C07D405/06 , C07C53/18 , C07F9/655
CPC classification number: A61K31/4535 , A61K31/341 , A61K31/381 , A61K31/4025 , A61K31/426 , A61K31/4525 , C07C53/18 , C07D277/20 , C07D277/56 , C07D307/68 , C07D333/38 , C07D405/06 , C07F9/3808 , C07F9/65515
Abstract: Compounds represented by formula (I):wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书中所定义，及其药学上可接受的盐可用作具有丝氨酸蛋白酶抑制作用的高血糖抑制剂和用作糖尿病的预防或治疗药物。
-
Patent Agency Ranking
公开(公告)号：US09346821B2
公开(公告)日：2016-05-24
申请号：US14098774
申请日：2013-12-06
Applicant: AJINOMOTO CO., INC.
Inventor： Tamotsu Suzuki , Takahiro Koshiba , Munetaka Tokumasu , Koji Ohsumi
IPC: C07D495/04 , C07D307/68 , C07D333/38 , C07D405/06 , C07D409/06 , C07D417/06 , A61K38/00
CPC classification number: C07D495/04 , A61K38/00 , C07D307/68 , C07D333/38 , C07D405/06 , C07D409/06 , C07D417/06
Abstract: The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I) wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.
Abstract translation: 本发明提供具有丝氨酸蛋白酶抑制作用的血糖升高抑制剂，其是用于肥胖症的新型治疗或预防剂。 由下式（I）表示的化合物或其药学上可接受的盐，其中每个符号如说明书中所述。
-
公开(公告)号：US09907766B2
公开(公告)日：2018-03-06
申请号：US15389639
申请日：2016-12-23
Applicant: AJINOMOTO CO., INC.
Inventor： Yoshiro Kitahara , Koji Ohsumi , Seiji Kitajima , Shimpei Ogawa
IPC: A61K31/17 , C07C335/20 , C07C335/16
CPC classification number: A61K31/17 , A61K31/277 , C07C335/16 , C07C335/20
Abstract: Sweetness receptor antagonists represented by formula (I): wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.
-
公开(公告)号：US20160058734A1
公开(公告)日：2016-03-03
申请号：US14934386
申请日：2015-11-06
Applicant: AJINOMOTO CO., INC.
Inventor： Takahiro KOSHIBA , Munetaka Tokumasu , Taisuke Ichimaru , Koji Ohsumi , Tadakiyo Nakagawa , Tatsuhiro Yamada , Kayo Matsumoto , Tamotsu Suzuki
IPC: A61K31/381 , A61K31/4025 , A61K31/4535 , A61K38/05 , A61K31/397 , A61K31/4725 , A61K31/396 , A61K31/41 , A61K31/19 , A61K31/4436
CPC classification number: A61K31/381 , A61K31/19 , A61K31/396 , A61K31/397 , A61K31/4025 , A61K31/41 , A61K31/4436 , A61K31/4535 , A61K31/4725 , A61K38/05 , C07D319/12 , C07D333/38 , C07D333/40 , C07D409/06 , C07D409/12
Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
-
公开(公告)号：US20150368242A1
公开(公告)日：2015-12-24
申请号：US14838419
申请日：2015-08-28
Applicant: Ajinomoto Co., Inc.
Inventor： Tamotsu Suzuki , Hiroki Inoue , Kayo Matsumoto , Takahiro Koshiba , Koji Ohsumi , Hiroki Ozawa , Munetaka Tokumasu , Masatsugu Noguchi
IPC: C07D471/04
CPC classification number: C07D471/04 , C07B59/002 , C07B2200/05
Abstract: An object is to provide a novel compound having a higher MGAT2 inhibitory activity than conventional compounds. A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof is provided.
Abstract translation: 目的是提供具有比常规化合物更高的MGAT2抑制活性的新化合物。 提供由以下通式（I）表示的化合物或其药学上可接受的盐。
-
公开(公告)号：US09115107B2
公开(公告)日：2015-08-25
申请号：US14496363
申请日：2014-09-25
Applicant: AJINOMOTO CO., INC.
Inventor： Atsushi Konishi , Munetaka Tokumasu , Tamotsu Suzuki , Takahiro Koshiba , Koji Ohsumi , Osamu Ikehara , Yuko Kodama
IPC: C07D307/68 , C07D277/20 , C07D277/56 , C07D333/38 , C07D405/06 , C07C53/18 , C07F9/655 , C07F9/38
CPC classification number: A61K31/4535 , A61K31/341 , A61K31/381 , A61K31/4025 , A61K31/426 , A61K31/4525 , C07C53/18 , C07D277/20 , C07D277/56 , C07D307/68 , C07D333/38 , C07D405/06 , C07F9/3808 , C07F9/65515
Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.
Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书中所定义，及其药学上可接受的盐可用作具有丝氨酸蛋白酶抑制作用的高血糖抑制剂和用作糖尿病的预防或治疗药物。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.019 seconds)
